MUSC Storm Eye Institute
Small-aperture optics can improve depth of focus without compromising vision
Pharmaceutical therapies for presbyopia may bridge gap until surgery is needed
Roundtable: Corneal consequences of chronic inflammation can be severe in children
VIDEO: Speaker talks about improving resident education
Smartphone app helps diagnose uveitis, reduce lab costs and testing
FDA panel scrutinizes LASIK safety data
GAITHERSBURG, Md. – Issues surrounding patient safety, patient satisfaction and even marketing practices associated with LASIK came under intense scrutiny since the U.S. Food and Drug Administration Ophthalmic Devices Panel heard public testimony in April in favor of and sometimes vehemently opposed to the surgery. Jayne S. Weiss, MD, chair of the FDA Ophthalmic Devices Panel, is involved in the FDA’s review of LASIK safety data. Based in part on the testimony and the passage of time since labeling information was last reviewed, the panel made recommendations to update labeling information as well as its own patient information Web site.